In this role, Raviraj will work closely with the CEO to shape growth strategy, lead mergers and acquisitions, strengthen investor relations, and drive digital transformation across finance and supply chain functions.
Concord Biotech is a globally recognized, R&D-driven biotechnology company focused on fermentation-based APIs and enzymes. Raviraj’s appointment reflects the company’s focus on disciplined financial leadership as it scales operations and expands its global footprint.
Before joining Concord Biotech, Raviraj served briefly in 2025 as Senior Vice President at Sakar Healthcare. There, he managed a wide portfolio covering finance, commercial operations, supply chain, and IT. His responsibilities included improving financial performance, treasury operations, compliance frameworks, and stakeholder engagement, while also supporting acquisition strategy and profitability initiatives.
Earlier, Raviraj spent nearly 10 years at Intas Pharmaceuticals as Global Lead – Internal Audit and Lead – Mergers & Acquisitions. During this period, he led complex cross-border audits across the USA, UK, Europe, and Asia, and worked closely with boards and private equity stakeholders. He played a key role in major transactions, including the acquisition of the Teva/Actavis entity, one of India’s largest outbound deals valued at GBP 600 million. He also structured more than USD 3 billion in borrowings and USD 0.8 billion in equity raises, while leading in-licensing, CDMO, and portfolio negotiations.
Raviraj’s earlier experience includes roles as Lead Commercial – Finance & Procurement at Lambda Therapeutic Research, where he handled finance, treasury, IPO readiness, and procurement automation. As Vice President – Finance at Shalby Limited, he supported acquisition-led growth, long-term funding strategies, and credit ratings, helping scale the organization from a 200-bed to a 2000-bed hospital network. At Gati Limited, part of the Allcargo Group, he led commercial finance, turnaround strategy, private equity investment processes, and divestments.
Raviraj began building his M&A and treasury expertise at Intas Pharmaceuticals as AGM – Finance, managing IPO processes, PE investments, ECB financing, and global acquisitions with borrowings exceeding INR 1100 crore. His early career at GVFL and Claris Lifesciences provided a strong base in venture investing, financial modeling, and corporate governance.
Also read: Viksit Workforce for a Viksit Bharat
Do Follow: The Mainstream formerly known as CIO News LinkedIn Account | The Mainstream formerly known as CIO News Facebook | The Mainstream formerly known as CIO News Youtube | The Mainstream formerly known as CIO News Twitter
About us:
The Mainstream is a premier platform delivering the latest updates and informed perspectives across the technology business and cyber landscape. Built on research-driven, thought leadership and original intellectual property, The Mainstream also curates summits & conferences that convene decision makers to explore how technology reshapes industries and leadership. With a growing presence in India and globally across the Middle East, Africa, ASEAN, the USA, the UK and Australia, The Mainstream carries a vision to bring the latest happenings and insights to 8.2 billion people and to place technology at the centre of conversation for leaders navigating the future.
